EP4531857
GCN2 MODULATOR FOR TREATING ADVANCED SOLID TUMORS OR BLOOD CANCER
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
25.5.2023EP published:
11.3.2026EP application number:
23733583.1
EPO information:
European Patent Register
Max expiry date:
24.5.2043Expiry date:
10.7.2026
Title in English:
GCN2 MODULATOR FOR TREATING ADVANCED SOLID TUMORS OR BLOOD CANCERLanguage of the patent:
English
Timeline
Today
25.5.2023EP application
11.3.2026EP Publication
10.7.2026Expires
Owner
Name:
Hibercell, Inc.Address:
619 West 54th Street, 8th Floor, New York, NY 10019, US
Inventor
Name:
BOSE, NanditaAddress:
New York, New York 10019, US
Name:
GARGANO, MicheleAddress:
New York, New York 10019, US
Name:
IGLESIAS, JoseAddress:
New York, New York 10019, US
Name:
MULVIHILL, Mark J.Address:
New York, New York 10019, US
Name:
OLIVER-SHAFFER, PatriciaAddress:
New York, New York 10019, US
Name:
SURGULADZE, DavidAddress:
New York, New York 10019, US
Name:
RAMURTHY, SavithriAddress:
New York, New York 10019, US
Name:
TAMEIRE, FevenAddress:
New York, New York 10019, US
Priority
Number:
202263345727 PDate:
25.5.2022Country:
US
Number:
202363440297 PDate:
20.1.2023Country:
US
Number:
202363443269 PDate:
3.2.2023Country:
US
Number:
202363455861 PDate:
30.3.2023Country:
US
Classification
Categories:
A61K 31/4985, A61P 35/00, A61P 35/02, A61K 45/06, A61K 31/496, A61K 31/513, A61K 39/00, A61K 31/4439, A61K 31/506